Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA

Dr. Xiaofan Zhu’s Four Study of Rare and Refractory Pediatric Hematologic Diseases  at 2023 EHA

2023.10.12
The 28th European Hematology Association (EHA) Annual Congress was held in Frankfurt, Germany, from June 8 to 11, 2023. Dr Xiaofan Zhu and his team from the Children's Hematology Center at the Chinese Academy of Medical Sciences and Peking Union Medical College presented four abstracts at this EHA congress. These abstracts covered various aspects of research, including the prognostic factors for relapsed childhood acute lymphoblastic leukemia (ALL) treated with the CCLG-ALL2008 protocol in China, the use of Blinatumomab for 14 days in combination with chemotherapy to achieve minimal residual disease (MRD) conversion in pediatric B-ALL patients, the integration of transcriptomic features to improve prognosis prediction in pediatric acute myeloid leukemia (AML) with KMT2A rearrangements, and the effective treatment of pediatric non-sickle cell anemia (NSAA) with Hydroxyurea in combination with CSA. To gain a deeper understanding of these studies, Dr. Zhu has provided interpretations of the research findings, which are summarized below.
Dr. Liu Hongxing and Wang Tong: Decoding Structural Aberrations of the PAX5 Gene in B-ALL and its Correlation with Diagnostic Classification and Treatment Outcomes

Dr. Liu Hongxing and Wang Tong: Decoding Structural Aberrations of the PAX5 Gene in B-ALL and its Correlation with Diagnostic Classification and Treatment Outcomes

2023.10.12
Acute B lymphoblastic leukemia (B-ALL) is a clonal heterogeneous disease caused by mutations in genes associated with the development and proliferation of B lymphocytes, which obstructs the normal differentiation and maturation of B lymphocyte progenitor cells. Although the complete remission rate for adult ALL patients can exceed 80% after induction remission therapy, most patients eventually relapse, resulting in a low long-term survival rate. Recently, many new gene mutation types have been detected in relapsed B-ALL patients using technologies such as gene chips and second-generation sequencing. However, the exact pathogenesis of these gene mutations and their co-synergistic fusion genes in B-ALL remains unclear. At the recently concluded 28th European Hematology Association (EHA) annual meeting, a study (Abstract No: P346) by the team of Liu Hongxing and Wang Tong from Beijing Lu Daopei Hematology Institute was selected for this year's EHA. The research aims to decode the structural changes of PAX5 and analyze other pathological fusion genes and gene mutations in B-ALL, while following up on the treatment and outcome of patients.
Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

2023.10.12
The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
Dr.  HuilaiZhang’s Team: Key Research in the Field of Hodgkin Lymphoma

Dr.  HuilaiZhang’s Team: Key Research in the Field of Hodgkin Lymphoma

2023.10.12
The 28th European Hematology Conference/Annual Meeting (28th EHA Congress) was successfully held in Frankfurt, Germany from June 8-11, 2023. The conference was organized by the European Hematology Association (EHA). As one of the largest international conferences in the field of hematology worldwide, the EHA annual meeting gathered top hematology experts from around the globe, covering all aspects of hematology research. The conference featured oral presentations, poster presentations, and several other sessions. This edition of Oncology Frontier focuses on key clinical studies on Hodgkin lymphoma presented in the oral report session, providing a quick overview of the latest research advancements in this area.
Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

2023.10.12
From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology.
Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

2023.10.12
From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr.  Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA.
Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

2023.10.12
Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows:
Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

2023.10.12
At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) held in Copenhagen, Dr. Xiaoting Hua of the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine unveiled significant findings. His research focused on mutations that mediate Acinetobacter baumannii's resistance and virulence to a new antibiotic, Cefiderocol.
Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

2023.10.12
Ventilator-Associated Pneumonia (VAP) continues to be a critical concern in intensive care units, leading to prolonged hospital stays and increased mortality rates. The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 unveiled crucial research findings shedding light on innovative approaches to VAP diagnosis and treatment. In this article, we present a synthesis of the key discoveries from ECCMID 2023, offering insights into the evolving landscape of VAP research.
Interview with Chao Zhuo at ECCMID 2023

Interview with Chao Zhuo at ECCMID 2023

2023.10.12
The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, from April 15th to 18th, 2023. As one of the most significant conferences in the field of clinical microbiology and infectious diseases, it marked a significant gathering after a three-year hiatus due to the pandemic. Chinese experts, including Dr. Chao Zhuo from The First Affiliated Hospital of Guangzhou Medical University, were present to share their insights.